Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ554MR)

This product GTTS-WQ554MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ554MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1611MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ3236MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ10260MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ751MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11587MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ8598MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ5706MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ13453MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW